Rallybio
Rare disease drugmaker · based in New Haven, United States · founded 2018 · rallybio.com
Rallybio works on 3 rare diseases we track, including Immune Thrombocytopenia, Myasthenia Gravis and 1 more.
Rallybio agreed in March 2026 to merge with Candid Therapeutics, but Candid ended the agreement in May 2026 to pursue a deal with UCB, and Rallybio received a termination fee and remains independent. Rallybio previously focused on antibodies and engineered proteins for rare diseases across hematology and other therapeutic areas.
Rallybio clinical trials
We did not find active Rallybio trials for the rare diseases we track on ClinicalTrials.gov right now.
Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only Rallybio. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
More about Rallybio
As a rare disease specialist, Rallybio has active clinical trial programs and drug development efforts across 3 rare diseases, including Immune Thrombocytopenia, Myasthenia Gravis, Thyroid Eye Disease. These programs may span orphan drug designation, novel therapeutic mechanisms, and precision medicine approaches targeting the underlying causes of each disease.
The clinical trials section below shows active and recruiting rare disease studies sponsored by Rallybio, sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites.
The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.
Rallybio is headquartered in New Haven, United States, founded in 2018. The company dedicates its research and development resources exclusively to rare and orphan diseases, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.
Rare diseases Rallybio works on
Each disease page lists every open trial, not only Rallybio's, plus approved treatments.
Immune thrombocytopenia (ITP) is a rare autoimmune disorder in which the immune system destroys platelets, the blood cells that stop bleeding, and slows their production.
How common: Estimated 9 to 20 per 100,000 people; children often have a temporary form that resolves within months
Myasthenia gravis is a chronic autoimmune neuromuscular disorder causing muscle weakness and rapid fatigue.
How common: 1 in 5,000 people
Thyroid eye disease (TED) is a rare autoimmune condition in which the immune system attacks the muscles and fat behind the eyes, causing bulging eyes, double vision, pain, and in severe cases vision...
How common: About 16 in 100,000 women and 3 in 100,000 men diagnosed each year; up to half of people with Graves' disease develop some degree of TED
Where to get support
Patient groups can explain a diagnosis, point you to specialists and tell you about trials before they open. Rallybio's own site is rallybio.com, and our help paying for treatment page lists drugmaker programs and charity funds.
- NIH National Heart, Lung, and Blood Institute - Immune ThrombocytopeniaImmune Thrombocytopenia
- National Organization for Rare Disorders (NORD) - Immune ThrombocytopeniaImmune Thrombocytopenia
- Myasthenia Gravis Foundation of America (MGFA)Myasthenia Gravis
- NIH GARD - Myasthenia GravisMyasthenia Gravis
- National Organization for Rare Disorders (NORD) - Thyroid Eye DiseaseThyroid Eye Disease
- American Thyroid AssociationThyroid Eye Disease